MiMedx Provides Update On Its Reimbursement Coverage

MARIETTA, Ga., Nov. 21, 2017 -- (Healthcare Sales & Marketing Network) -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading biopharmaceutical company developing and marketing regenerative and therapeutic biologics utilizing human placental tissue allografts ... Regenerative Medicine, Reimbursement MiMedx, EpiFix, Venous Leg Ulcer, Diabetic Foot Ulcer
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news